. . . . . . "4.6\tFertilita, t\u011Bhotenstv\u00ED a kojen\u00ED"@cs . "T\u011Bhotenstv\u00ED: \nU\u017E\u00EDv\u00E1n\u00ED antagonist\u016F angiotenzinu II se b\u011Bhem prvn\u00EDho trimestru t\u011Bhotenstv\u00ED nedoporu\u010Duje (viz bod 4.4). U\u017E\u00EDv\u00E1n\u00ED antagonist\u016F angiotenzinu II je v druh\u00E9m a t\u0159et\u00EDm trimestru t\u011Bhotenstv\u00ED kontraindikov\u00E1no (viz body 4.3 a 4.4). \nEpidemiologick\u00E1 data t\u00FDkaj\u00EDc\u00ED se rizika teratogenity po u\u017E\u00EDv\u00E1n\u00ED ACE inhibitor\u016F b\u011Bhem prvn\u00EDho trimestru t\u011Bhotenstv\u00ED nejsou p\u0159esv\u011Bd\u010Div\u00E1; nicm\u00E9n\u011B mal\u00E9 zv\u00FD\u0161en\u00ED rizika nelze vylou\u010Dit. Zat\u00EDmco kontrolovan\u00E1 epidemiologick\u00E1 data t\u00FDkaj\u00EDc\u00ED se rizik p\u0159i u\u017E\u00EDv\u00E1n\u00ED antagonist\u016F angiotenzinu II nejsou, podobn\u00E1 rizika by mohla existovat i pro tuto skupinu l\u00E9k\u016F. Pokud nen\u00ED pokra\u010Dov\u00E1n\u00ED l\u00E9\u010Dby antagonisty angiotenzinu II pova\u017Eov\u00E1no za nezbytn\u00E9, pacientky pl\u00E1nuj\u00EDc\u00ED t\u011Bhotenstv\u00ED mus\u00ED b\u00FDt p\u0159evedeny na alternativn\u00ED antihypertenziva, kter\u00E1 maj\u00ED pro u\u017E\u00EDv\u00E1n\u00ED v t\u011Bhotenstv\u00ED stanoven bezpe\u010Dnostn\u00ED profil. Pokud pacientka ot\u011Bhotn\u00ED, l\u00E9\u010Dba antagonisty angiotenzinu II mus\u00ED b\u00FDt okam\u017Eit\u011B ukon\u010Dena, a je-li to vhodn\u00E9, mus\u00ED b\u00FDt zah\u00E1jena alternativn\u00ED l\u00E9\u010Dba. \nJe zn\u00E1mo, \u017Ee u\u017E\u00EDv\u00E1n\u00ED antagonist\u016F angiotenzinu II b\u011Bhem druh\u00E9ho a t\u0159et\u00EDho trimestru p\u016Fsob\u00ED toxicky na plod (sn\u00ED\u017Een\u00E1 funkce ledvin, oligohydramnion, retardace osifikace lebky) a na novorozence (selh\u00E1n\u00ED ledvin, hypotenze, hyperkal\u00E9mie) (viz tak\u00E9 bod 5.3). \nJestli\u017Ee do\u0161lo k u\u017E\u00EDv\u00E1n\u00ED antagonist\u016F angiotenzinu II od druh\u00E9ho trimestru t\u011Bhotenstv\u00ED, doporu\u010Duje se vy\u0161et\u0159en\u00ED ledvin a lebky ultrazvukem. \nKojenci, jejich\u017E matky u\u017E\u00EDvaly antagonisty angiotenzinu II, mus\u00ED b\u00FDt pe\u010Dliv\u011B pozorov\u00E1ni kv\u016Fli hypotenzi (viz body 4.3 a 4.4).\nKojen\u00ED: \nOlmesartan se vylu\u010Duje do ml\u00E9ka samic potkan\u016F, ale nen\u00ED zn\u00E1mo, zda se vylu\u010Duje tak\u00E9 do mate\u0159sk\u00E9ho ml\u00E9ka u lid\u00ED. Proto\u017Ee nejsou k dispozici \u017E\u00E1dn\u00E9 informace o u\u017E\u00EDv\u00E1n\u00ED p\u0159\u00EDpravku Zeota v obdob\u00ED kojen\u00ED, u\u017E\u00EDv\u00E1n\u00ED p\u0159\u00EDpravku Zeota se nedoporu\u010Duje a preferuj\u00ED se alternativn\u00ED l\u00E9ky s l\u00E9pe stanoven\u00FDm bezpe\u010Dnostn\u00EDm profilem v obdob\u00ED kojen\u00ED, a to zejm\u00E9na pokud je kojeno novorozen\u00E9 nebo p\u0159ed\u010Dasn\u011B narozen\u00E9 d\u00EDt\u011B.\n"@cs . . . "004.006" . .